Abstract
During the early stages of clinical trials with live attenuated rubella vaccines about a decade ago, two important questions were paramount in the minds of those responsible for those trials. The first was concerned with the possible communicability of the vaccine virus and the second with the duration of immunity. It must be accepted that any new vaccine poses problems, both general and specific, but as far as rubella vaccines were concerned, these were of special importance. The first question arose from the original trials in a small group of susceptible children carried out by Parkman et al 1 and Meyer et al 2 with their high passage virus (HPV-77) prepared in monkey kidney cell cultures. They had shown that intermittent excretion of rubella vaccine virus occurred in the majority of vaccinated individuals. The question was simple. If vaccinees excreted virus in the nasopharynx, could infection be transmitted to susceptible
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
